Abstract Body

Estimation of time of HIV infection can be useful in epidemiological studies of incidence of infection, in establishing a link to probable risk behavior, and in narrowing the search for likely partners to whom infection could have been passed. Current HIV Recency assays such as the BED CEIA and  HIV-1 Limiting Antigen (LAg)-Avidity EIA have major limitations due to variable immune response among individuals, variability in different HIV-1 subtypes, and false recency rates in some individuals.  Sequential bleeds from recently HIV infected individuals exhibits progressive appearance of specific Western blot (WB) bands which can be utilized to estimate time of infection.  We examined WB profiles of closely spaced bleeds from newly infected individuals from the RV217 ECHO trial to generate a WB Index (WBI) which can be useful as a measure of recency of infection.

Individuals at high risk of HIV infection in Kenya, Uganda, Tanzania and Thailand were monitored twice weekly by HIV RNA Aptima assay (Hologic, LaJolla, CA), the earliest available indicator of infection.Blood from first time RNA positive individuals was collected at frequent intervals and tested by Western blot (Bio-Rad, Hercules, CA).Bands were grouped according to timing of appearance, the intensities of each band was scored from 0-2+, and individual intensities or sums of bands plotted as time after first detection of infection.

Figure 1 shows the relative intensity of bands from 20 seroconverting individuals post first Aptima RNA positivity.Antibodies to p24, p40, gp160 and p55 (A Bands) develop quickly after infection, with maximum reactivity by 25-40 days post infection.A more slowly evolving response is seen for p31, p65, gp41, gp120 and p51, (B Bands).A WBI of A and B bands can be used to estimate time post infection between 15 days to up to 270 days with some consistency.The subtypes included in this analysis include A, B, C, D, and CRF_01AE, all of which show similar evolution profiles.

    ,

  1. The WBI accurately distinguishes between new, well established, or advanced infection and provides a useful estimate of the time of HIV infection.
  2. ,

  3. Is independent of virus subtype and applicable to different populations;
  4. ,

  5. Uses results from an assay already used for confirmation of HIV infection, allowing for greater flexibility in application (including developing countries)
  6. ,

  7. Demonstrates a low False Recency Rate, thereby offering a more accurate measurement of incidence.